8-K: Milestone Pharma Secures FDA Approval for CARDAMYST PSVT Nasal Spray

Milestone Pharmaceuticals announced FDA approval for CARDAMYST (etripamil) nasal spray, the first self-administered treatment for acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) in adults.

Summary

• The U.S. Food and Drug Administration (FDA) has approved Milestone Pharmaceuticals Inc.'s New Drug Application for CARDAMYST (etripamil) nasal spray for the management of paroxysmal supraventricular tachycardia (PSVT) in adults.
• CARDAMYST is the first FDA-approved treatment in over 30 years for PSVT and the first and only self-administered nasal spray for this condition, affecting more than 2 million Americans.
• The product is expected to be available in retail pharmacies in the first quarter of 2026.
• Clinical data from the Phase 3 RAPID trial showed that participants using CARDAMYST were two times more likely to convert symptomatic PSVT to sinus rhythm and did so more than three times faster compared to placebo.
• Specifically, 64% of CARDAMYST users converted to sinus rhythm within 30 minutes, compared to 31% on placebo (HR = 2.62; p<0.001), with a median time to conversion of 17 minutes for CARDAMYST versus 54 minutes for placebo.
• The company is well-capitalized for the launch and commercialization of CARDAMYST, with $82.6 million in cash, cash equivalents, and short-term investments as of September 30, 2025, and an anticipated $75.0 million from royalty financing.
• Milestone plans to leverage this approval to advance a Phase 3 program for etripamil in atrial fibrillation with rapid ventricular rate (AFib-RVR) via a supplemental New Drug Application (sNDA) pathway.

Sentiment

Score: 9

Explanation: The FDA approval of CARDAMYST is a transformative event for Milestone Pharmaceuticals, introducing a first-in-class, self-administered treatment for a large patient population with significant unmet needs. This, combined with strong clinical data and solid financial backing for launch, indicates a highly positive outlook.

Positives

• FDA approval of CARDAMYST (etripamil) nasal spray, marking the first new treatment for PSVT in over 30 years.
• CARDAMYST is the first and only self-administered nasal spray for PSVT, offering patients a novel, at-home treatment option.
• Strong clinical efficacy demonstrated in the Phase 3 RAPID trial, showing 2x greater likelihood and 3x faster conversion to sinus rhythm compared to placebo.
• The drug was well-tolerated in clinical studies, with most adverse events being mild-to-moderate and transient, primarily localized to the nasal administration site.
• Milestone Pharmaceuticals is well-capitalized with $82.6 million in cash as of September 30, 2025, and an additional $75.0 million expected from royalty financing to support the launch.
• The approval enables the development of etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR) under an sNDA pathway, potentially expanding the drug's market.

Risks

• Risks inherent in biopharmaceutical product development and clinical trials.
• Uncertainties related to the timing of initiation, enrollment, completion, evaluation, and results of future clinical trials.
• Complexity inherent in cleaning, verifying, and analyzing trial data.
• Whether future interactions with the FDA will have satisfactory outcomes.
• General economic, political, and market conditions, including investor concerns regarding inflation, international tariffs, Russian hostilities in Ukraine, and ongoing disputes in the Middle East.
• Overall fluctuations in financial markets in the United States and abroad.
• Risks related to pandemics and public health emergencies.
• Risks related to the sufficiency of capital resources and the ability to raise additional capital in the current economic climate.

Future Outlook

Milestone Pharmaceuticals plans to launch CARDAMYST in retail pharmacies in the first quarter of 2026, focusing on securing insurance coverage and establishing distribution. The company aims to reach approximately half of the annually treated PSVT patients by targeting around 10,000 prescribers with a sales force of about 60 representatives. Additionally, Milestone intends to initiate a Phase 3 registrational program for etripamil in atrial fibrillation with rapid ventricular rate (AFib-RVR) under a supplemental New Drug Application pathway, leveraging existing PSVT program data.

Management Comments

• Joseph Oliveto, President and CEO: "The FDA approval of CARDAMYST is a watershed moment for Milestone and a gratifying event for our team members, patients, clinical investigators, and health care providers who participated in the development program."
• James Ip, M.D., FACC, FHRS, etripamil investigator: "CARDAMYST will give many of them the ability to administer a medication themselves that can quickly stop their PSVT episode and potentially avoid a hospital trip or a call to emergency services."
• Lorenz Muller, Chief Commercial Officer: "Our goal is that CARDAMYST will become a trusted and essential solution for healthcare providers and their patients."
• Annette Greene, CARDAMYST clinical trial participant: "Adults with SVT have been waiting a long time for the day when they can confidently self-administer CARDAMYST to treat their SVT episodes. It is very exciting that the day has become a reality."

Industry Context

The approval of CARDAMYST addresses a significant unmet need in the treatment of Paroxysmal Supraventricular Tachycardia (PSVT), a condition affecting over 2 million Americans. Current treatment options often involve intravenous administration in healthcare settings, emergency department visits, or invasive procedures like catheter ablation (elected by only ~15% of eligible patients). CARDAMYST's self-administered nasal spray offers a novel, convenient, and rapid-acting alternative, potentially reducing healthcare resource utilization (ED visits, hospitalizations) and empowering patients to manage their condition outside of clinical settings. This positions CARDAMYST as a disruptive innovation in the PSVT market, which has seen no new FDA-approved treatments in over 30 years.

Comparison to Industry Standards

• CARDAMYST is the first FDA-approved treatment for PSVT in over 30 years, distinguishing it from older, established therapies.
• It is the first and only self-administered nasal spray for PSVT, offering a significant advantage over traditional IV-administered treatments (e.g., adenosine, verapamil, diltiazem) that require a healthcare setting.
• The product provides a non-invasive alternative to catheter ablation, which is an invasive procedure elected by only approximately 15% of eligible U.S. PSVT patients due to reluctance and availability issues.
• CARDAMYST offers a more reliable and rapid solution compared to off-label 'pill in pocket' oral calcium channel blockers or beta blockers, or vagal maneuvers, which are often poorly effective or inconvenient.

Stakeholder Impact

• Shareholders: Highly positive impact due to FDA approval of a novel, first-in-class product with significant market potential, likely leading to increased valuation and future revenue streams.
• Patients (with PSVT): Significant positive impact by providing a rapid-acting, self-administered treatment option, empowering them to manage episodes outside of emergency settings, reducing anxiety, and improving quality of life.
• Healthcare Providers: Provides a new, trusted calcium channel blocker solution with robust clinical data, potentially freeing up their time and office resources by reducing the need for in-clinic or emergency interventions.
• Payers (Insurers): Potential for cost offsets driven by lower healthcare resource utilization (reduced ED visits and hospital admissions), supporting coverage and rational pricing.
• Employees: Positive impact through job security, potential growth opportunities, and morale boost from a successful product approval and launch.

Next Steps

• Make CARDAMYST available in retail pharmacies in the first quarter of 2026.
• Actively work to secure insurance coverage for CARDAMYST.
• Begin distribution of CARDAMYST through retail pharmacies.
• Implement commercial plans, including a sales force targeting approximately 10,000 prescribers with 60 sales representatives.
• Initiate a Phase 3 registrational program for etripamil in atrial fibrillation with rapid ventricular rate (AFib-RVR) under a supplemental New Drug Application (sNDA) pathway.

Key Dates

Recommendation

The FDA approval of CARDAMYST represents a monumental achievement for Milestone Pharmaceuticals, introducing a first-in-class, self-administered treatment for a large and underserved patient population with PSVT. This drug addresses a significant unmet medical need, offering convenience and rapid efficacy that could substantially reduce emergency department visits and hospitalizations. The company is well-capitalized for the commercial launch, and the approval also de-risks and paves the way for a potential second indication in AFib-RVR, significantly expanding future market opportunities. The unique market position, strong clinical data, and clear commercialization strategy make this a compelling investment opportunity.

Keywords

CARDAMYST, etripamil, PSVT, Paroxysmal Supraventricular Tachycardia, FDA Approval, Nasal Spray, Calcium Channel Blocker, Arrhythmia, Biopharmaceutical, Milestone Pharmaceuticals, AFib-RVR